Europe’s high court strikes blow to drug companies in ‘pay-for-delay’ case

Pharmaceuticals

The U.K. Competition and Markets Authority won a victory in a decision by Europe’s high court, ruling GlaxosmithKline’s entering of a financial deal with industry rivals to delay the generic version of its drugs violates EU competition law.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.